Funding Shortfall Impedes Progress Of Stanford's Science

PALO ALTO, CALIF.—Faced with an unexpected dearth of donations, Stanford University may be forced to slow down development of its Near West campus, the innovative, 41-acre science megacomplex designed to pave the way for decades of 21st-century research. As originally planned, a major part of the $350 million project was scheduled for completion in 1994. The slowdown could mean that some of Stanford’s science faculty will have to wait as much as four years longer than expected fo

Written byRobert Buderi
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

PALO ALTO, CALIF.—Faced with an unexpected dearth of donations, Stanford University may be forced to slow down development of its Near West campus, the innovative, 41-acre science megacomplex designed to pave the way for decades of 21st-century research. As originally planned, a major part of the $350 million project was scheduled for completion in 1994. The slowdown could mean that some of Stanford’s science faculty will have to wait as much as four years longer than expected for their new facilities.

So far, development is on schedule for the first phase of what planners have designed as a two-part construction process. The Keck Science Building—a general science facility—is already in operation, a biology facility is under construction, and a building dedicated to advanced materials research is scheduled for groundbreaking this summer. But a host of other planned phase-one construction projects—including two buildings for information sciences research, and one each for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies